Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01189370 · ClinicalTrials.gov registry record · Phase 2
Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer
A Phase 2 study of Renal Cell Cancer, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT01189370: Completed Phase 2 study of Renal Cell Cancer, sponsored by University of Kansas Medical Center.
NCT01189370 is a Phase 2 study of Renal Cell Cancer that has completed, run by University of Kansas Medical Center. The registered enrollment target is 25 participants, below the 124-participant average among 10 other Renal Cell Cancer trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01189370, a Phase 2 study of Renal Cell Cancer, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether an increase in the dose of sorafenib when given over five instead of 7 days/week, will result in an improvement of the response rate (degree of shrinkage of your cancer) and an improvement in the length of time that sorafenib will control your cancer, without causing a significant increase in side effects.
Primary Outcome
Tolerability will be defined as successful completion of the dose level without experiencing Grade 3 or 4 toxicity.
Conditions Studied
Interventions
- DRUG sorafenib
Study Locations (1)
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-06 |
| Est. Completion | 2015-04 |
| Phase | Phase 2 |
What the finished NCT01189370 record still lists
NCT01189370 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 124-participant average among 10 other Renal Cell Cancer trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Renal Cell Cancer appearing as the primary indexed condition, and to 1 intervention - of which sorafenib is the first listed.
NCT01189370 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT01189370 about?
NCT01189370 is a clinical study titled "Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer". The purpose of this study is to determine whether an increase in the dose of sorafenib when given over five instead of 7 days/week, will result in an improvement of the response rate (degree of shrinkage of your cancer) and an improvement in the length of time that sorafenib will control your cancer...
What is the current status of trial NCT01189370?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2008-06. Estimated completion is 2015-04.
What conditions does trial NCT01189370 study?
This clinical trial studies the following conditions: Renal Cell Cancer.
What interventions are being tested in trial NCT01189370?
The interventions under investigation include: sorafenib (DRUG).
Who is sponsoring clinical trial NCT01189370?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01189370 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01189370's enrollment target sits among peer trials
25 8th of 10 higher than 3 of 10 other Renal Cell Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Cell Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
ACTIVE NOT RECRUITING · Phase 2
-
Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery
COMPLETED · Phase 2
-
Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity
COMPLETED · Phase 2
-
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
RECRUITING · Phase 1
-
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia